MX374468B - Composicion farmaceutica acuosa semisolida que contiene tapentadol. - Google Patents

Composicion farmaceutica acuosa semisolida que contiene tapentadol.

Info

Publication number
MX374468B
MX374468B MX2016016703A MX2016016703A MX374468B MX 374468 B MX374468 B MX 374468B MX 2016016703 A MX2016016703 A MX 2016016703A MX 2016016703 A MX2016016703 A MX 2016016703A MX 374468 B MX374468 B MX 374468B
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
composition containing
semi
aqueous pharmaceutical
solid aqueous
Prior art date
Application number
MX2016016703A
Other languages
English (en)
Spanish (es)
Inventor
Eva Wulsten
Marc Schiller
Roger Carolus Augusta Embrechts
Sabine Karine Katrien Inghelbrecht
Ulrich Feil
Ulrich Reinhold
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of MX374468B publication Critical patent/MX374468B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
MX2016016703A 2011-03-04 2012-03-02 Composicion farmaceutica acuosa semisolida que contiene tapentadol. MX374468B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161449329P 2011-03-04 2011-03-04
EP11003603 2011-05-03
PCT/EP2012/000906 WO2012119729A1 (en) 2011-03-04 2012-03-02 Semisolid aqueous pharmaceutical composition containing tapentadol

Publications (1)

Publication Number Publication Date
MX374468B true MX374468B (es) 2025-03-06

Family

ID=44652117

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016016703A MX374468B (es) 2011-03-04 2012-03-02 Composicion farmaceutica acuosa semisolida que contiene tapentadol.
MX2013010100A MX344473B (es) 2011-03-04 2012-03-02 Composicion farmaceutica acuosa semisolida que contiene tapentadol.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2013010100A MX344473B (es) 2011-03-04 2012-03-02 Composicion farmaceutica acuosa semisolida que contiene tapentadol.

Country Status (24)

Country Link
US (3) US9446008B2 (enExample)
EP (3) EP3766489B1 (enExample)
JP (3) JP6027549B2 (enExample)
KR (2) KR102039320B1 (enExample)
CN (1) CN103501774A (enExample)
AU (2) AU2012224954C1 (enExample)
BR (1) BR112013022556A8 (enExample)
CA (1) CA2828637C (enExample)
CY (1) CY1119725T1 (enExample)
DK (1) DK2680834T3 (enExample)
EA (2) EA033171B1 (enExample)
ES (2) ES2910085T3 (enExample)
HR (1) HRP20171836T1 (enExample)
HU (1) HUE037491T2 (enExample)
IL (2) IL227826B (enExample)
LT (1) LT2680834T (enExample)
MX (2) MX374468B (enExample)
NO (1) NO2680834T3 (enExample)
PL (1) PL2680834T3 (enExample)
PT (2) PT3766489T (enExample)
RS (1) RS56692B1 (enExample)
SI (1) SI2680834T1 (enExample)
WO (1) WO2012119729A1 (enExample)
ZA (1) ZA201306480B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3685827A1 (en) 2011-03-04 2020-07-29 Grünenthal GmbH Aqueous pharmaceutical formulation of tapentadol for oral administration
PT3766489T (pt) 2011-05-03 2022-04-07 Gruenenthal Gmbh Composição farmacêutica aquosa semissólida contendo tapentadol
US8997860B2 (en) 2011-08-05 2015-04-07 Halliburton Energy Services, Inc. Methods for monitoring the formation and transport of a fracturing fluid using opticoanalytical devices
US9395306B2 (en) 2011-08-05 2016-07-19 Halliburton Energy Services, Inc. Methods for monitoring fluids within or produced from a subterranean formation during acidizing operations using opticoanalytical devices
US9228940B2 (en) 2012-09-14 2016-01-05 Halliburton Energy Services, Inc. Systems, methods, and apparatuses for in situ monitoring of cement fluid compositions and setting processes thereof
US8619256B1 (en) 2012-09-14 2013-12-31 Halliburton Energy Services, Inc. Systems and methods for monitoring the properties of a fluid cement composition in a flow path
US20140076550A1 (en) 2012-09-14 2014-03-20 Halliburton Energy Services, Inc. Systems and Methods for Detecting Microannulus Formation and Remediation
EP3027214A1 (en) * 2013-08-02 2016-06-08 ratiopharm GmbH Composition comprising tapentadol in a dissolved form
EP2845625A1 (en) 2013-09-04 2015-03-11 Grünenthal GmbH Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome
JP6923447B2 (ja) * 2015-03-27 2021-08-18 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング タペンタドールの非経口投与のための安定な製剤
EP3515412B1 (en) 2016-09-23 2025-04-23 Grünenthal GmbH Stable formulation for parenteral administration of tapentadol
WO2020020879A1 (en) * 2018-07-24 2020-01-30 Dr. August Wolff Gmbh & Co. Kg Arzneimittel Topical emulsion of an anticholinergic compound
KR102928295B1 (ko) 2018-09-07 2026-02-13 알.피.쉐러 테크놀러지즈 엘엘씨 경화 및 낮은 hlb 계면 활성제(들)의 첨가를 통한 고체 또는 반고체 지질 기반 제형 안정화
US12447119B2 (en) 2019-03-18 2025-10-21 Sunstar Americas, Inc. Oral care composition

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775678A (en) * 1984-10-01 1988-10-04 Schering Corporation Clotrimazole cream
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
US6183758B1 (en) * 1998-01-29 2001-02-06 Highland Laboratories, Inc. Phytochemicals, nutrients & medication absorption &/or treatment
US6399087B1 (en) 2000-12-20 2002-06-04 Amphastar Pharmaceuticals, Inc. Propofol formulation with enhanced microbial inhibition
US20050176790A1 (en) * 2001-02-28 2005-08-11 Johannes Bartholomaus Pharmaceutical salts
DE10109763A1 (de) 2001-02-28 2002-09-05 Gruenenthal Gmbh Pharmazeutische Salze
PE20030527A1 (es) 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
PT1485078E (pt) 2002-03-15 2013-01-14 Cypress Bioscience Inc Milnacipran para o tratamento do síndrome do intestino irritável
US20030191187A1 (en) 2002-04-01 2003-10-09 Lee Fang Yu Injectable pharmaceutical composition containing a non-steroidal anti-inflammatory drug and method for preparing the same
MXPA05002728A (es) 2002-09-13 2005-07-25 Cydex Inc Capsulas que contienen composiciones de relleno acuoso estabilizadas con ciclodextrina derivada.
US20040180915A1 (en) 2003-03-14 2004-09-16 Xanodyne Pharmacal, Inc. Methadone-containing compositions for parenteral administration and method of use thereof
WO2005112926A1 (en) 2004-05-17 2005-12-01 Pharmacofore, Inc. Compositions and methods for treating or preventing pain
ES2291780T3 (es) 2004-06-28 2008-03-01 Grunenthal Gmbh Formas cristalinas del clorhidrato de (-)-(1r,2r)-3-(3-dimetilamino-1-etil-2-metilpropil)fenol.
AR053304A1 (es) 2004-07-01 2007-05-02 Gruenenthal Gmbh Formas farmaceuticas orales protegidas frente al abuso con liberacion controlada de (1r,2r)-3-(3 dimetilamino-1-etil-2metil-propil)fenol y procedimiento para su produccion.
CA2606947A1 (en) 2005-04-28 2006-11-02 Theraquest Biosciences Llc Methods and compositions for treating pain
TWI329334B (en) 2005-12-02 2010-08-21 Chung Shan Inst Of Science Manufacture method of electromagnetic interference layer for the plasma display panel
US20080039405A1 (en) * 2006-04-25 2008-02-14 Croda, Inc. Modification of percutaneous absorption of topically active materials
CN102675136B (zh) 2006-04-28 2016-01-20 格吕伦塔尔有限公司 包含3-(3-二甲基氨基-1-乙基-2-甲基-丙基)-苯酚和nsaid的药物组合物
CN101431990B (zh) 2006-04-28 2011-08-03 格吕伦塔尔有限公司 包含3-(3-二甲基氨基-1-乙基-2-甲基-丙基)-酚和对乙酰氨基酚的药物结合
SI2046726T1 (sl) 2006-07-24 2010-05-31 Janssen Pharmaceutica Nv Priprava R R metoksifenil N N trimetilpentanamina
DE102007012165A1 (de) 2007-03-12 2008-09-18 Grünenthal GmbH Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie des Neuropathieschmerzes
EP1985292A1 (en) 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol
MX2010005680A (es) 2007-11-23 2010-12-21 Protect Pharmaceutical Corp Composiciones de tapentadol.
TWI454288B (zh) 2008-01-25 2014-10-01 Gruenenthal Chemie 藥物劑型
SI2352494T1 (sl) 2008-10-30 2019-12-31 Gruenenthal Gmbh Nove in potentne dozirne oblike tapentadola
WO2010100477A2 (en) 2009-03-03 2010-09-10 Shire Llc Amino acid and peptide carbamate prodrugs of tapentadol and uses thereof
US20100272815A1 (en) 2009-04-28 2010-10-28 Actavis Group Ptc Ehf Amorphous form of tapentadol hydrochloride
WO2011083304A1 (en) * 2010-01-05 2011-07-14 Shire Llc Prodrugs of opioids and uses thereof
CA2794734C (en) * 2010-03-30 2017-12-12 Phosphagenics Limited Transdermal delivery patch
GB201006200D0 (en) 2010-04-14 2010-06-02 Ayanda As Composition
US20120270848A1 (en) * 2010-10-22 2012-10-25 Galleon Pharmaceuticals, Inc. Novel Compositions and Therapeutic Methods Using Same
PT3766489T (pt) * 2011-05-03 2022-04-07 Gruenenthal Gmbh Composição farmacêutica aquosa semissólida contendo tapentadol

Also Published As

Publication number Publication date
EA201600442A1 (ru) 2017-02-28
CA2828637C (en) 2019-06-11
KR101911362B1 (ko) 2018-10-25
IL227826A0 (en) 2013-09-30
BR112013022556A2 (pt) 2016-12-06
US9446008B2 (en) 2016-09-20
EP3766489B1 (en) 2022-03-16
JP2014506900A (ja) 2014-03-20
MX2013010100A (es) 2013-10-01
US20160346229A1 (en) 2016-12-01
AU2012224954A1 (en) 2013-09-19
CA2828637A1 (en) 2012-09-13
IL258357A (en) 2018-05-31
JP2018065839A (ja) 2018-04-26
AU2017200040A1 (en) 2017-02-02
CN103501774A (zh) 2014-01-08
EA025194B1 (ru) 2016-11-30
WO2012119729A1 (en) 2012-09-13
RS56692B1 (sr) 2018-03-30
EP3766489A1 (en) 2021-01-20
KR102039320B1 (ko) 2019-11-01
EP3290029A1 (en) 2018-03-07
EP3290029B1 (en) 2020-09-02
JP6027549B2 (ja) 2016-11-16
ES2910085T3 (es) 2022-05-11
JP6670283B2 (ja) 2020-03-18
EP2680834A1 (en) 2014-01-08
PT3766489T (pt) 2022-04-07
PL2680834T3 (pl) 2018-03-30
PT2680834T (pt) 2018-01-25
ES2654407T3 (es) 2018-02-13
BR112013022556A8 (pt) 2018-01-16
EA033171B1 (ru) 2019-09-30
AU2012224954B2 (en) 2016-10-20
AU2017200040B2 (en) 2018-09-06
CY1119725T1 (el) 2018-06-27
JP2017039756A (ja) 2017-02-23
MX344473B (es) 2016-12-16
HUE037491T2 (hu) 2018-09-28
EA201300988A1 (ru) 2014-06-30
HRP20171836T1 (hr) 2017-12-29
SI2680834T1 (en) 2018-01-31
KR20180116463A (ko) 2018-10-24
US20120225950A1 (en) 2012-09-06
ZA201306480B (en) 2014-05-28
US20180133174A1 (en) 2018-05-17
AU2012224954C1 (en) 2017-04-06
JP6259042B2 (ja) 2018-01-10
LT2680834T (lt) 2018-01-10
KR20140013020A (ko) 2014-02-04
EP2680834B1 (en) 2017-10-18
IL227826B (en) 2018-04-30
NO2680834T3 (enExample) 2018-03-17
DK2680834T3 (en) 2017-12-04

Similar Documents

Publication Publication Date Title
CY1119725T1 (el) Ημιστερεη υδατικη φαρμακευτικη συνθεση που περιεχει ταπενταδολη
JOP20180102B1 (ar) مركب صيدلاني
CR20130406A (es) Composiciones farmacéuticas que comprenden anticuerpos humanos frente a pcsk9
CR20150120A (es) Nuevos derivados bicíclicos
EA201692443A1 (ru) Водная фармацевтическая композиция тапентадола для перорального введения
UA111717C2 (uk) Склад для перорального введення і ліпофільні солі метилналтрексону
MX340983B (es) Composiciones farmaceuticas y nutraceuticas de acido abscisico.
EA201590296A1 (ru) Дейтерированный ибрутиниб
ECSP11011391A (es) Métodos y productos intermedios para preparar agentes farmacéuticos
BR112015000329A2 (pt) formulações de diclofenac
BR112012032008A2 (pt) anticorpos s100a4 e usos terapêuticos do mesmo
ECSP15010550A (es) Preparación farmacéutica sólida que contiene levotiroxina
CO6920289A2 (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib.
CO7010828A2 (es) Preparación farmacéutica que comprende ߖciclodextrina sustituida
CO7160080A2 (es) Composiciones lipídicas de racecadotrillo
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
EA201491300A1 (ru) Композиция для назального применения с улучшенной стабильностью
BR112014029874A2 (pt) composições farmacêuticas tópicas de tipo emulsão o/a que contém um retinoide.
BR112015014078A2 (pt) composição farmacêutica oftalmológica tópica que contém regorefenib
CO6761388A2 (es) Composiciones pharmaceuticas que comprenden alisporivir
EP2851075A4 (en) PREPARATION WITH 6,7-UNSATED 7-CARBAMOYLMORPHINANE DERIVATIVE
BR112013029778A2 (pt) composição farmacêutica que compreende fexofenadina
PT2594266E (pt) Composições farmacêuticas sólidas que contêm sais de ibuprofeno
CO6801771A2 (es) Composición oral que comprende sodio divalproexy proceso para preparar la misma
GT201200066A (es) Nuevos derivados dihidro-oxazolobenzodiazepinonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen